CEO OGYX

Description

**OGYX \| High\-Throughput Organ\-on\-a\-Chip Platform** **CEO \& Co\-Founder Opportunity \|** Deeptech BioEngineering \| Drug Discovery Are you looking for an entrepreneurial opportunity at the intersection of **microfluidics, advanced in\-vitro** models and drug discovery, with the chance to build a high\-impact deep\-tech spin\-off? **OGYX** is developing a cost\-effective, robust and user\-friendly **microfluidic Organ\-on\-a\-Chip platform** designed for high\-throughput in\-vitro assays in research, drug development and toxicology. Backed by Leitat and a strong technical team, the project is now seeking an entrepreneurial CEO to lead the creation of the spin\-off and drive its commercial and strategic development. As **CEO \& Co\-Founder**, you will lead the venture\-building journey together with the scientific and technical team, shaping the business model, early market traction and fundraising strategy of a company with the potential to become a preferred platform provider in the Organ\-on\-a\-Chip market. **About OGYX** Drug discovery still relies heavily on **animal models and conventional in\-vitro systems**, both of which often fail to accurately replicate human physiology. This results in poor predictive power, major development inefficiencies and growing ethical and regulatory pressure to reduce animal testing. Organ\-on\-a\-Chip technologies offer a promising alternative, but current solutions face important limitations: they often compromise essential 2D/3D co\-culture features, require peripheral equipment, or are not well suited for multiplexed high\-throughput readouts and scalable production. OGYX addresses this challenge with a microfluidic OoC plate designed for **high\-throughput screening**, compatible with **2D/3D co\-cultures and organoids**, and readable with standard multi\-well plate readers. Its design combines biological relevance, usability and manufacturability in a single platform. **Why OGYX** * **Novel Organ\-on\-a\-Chip plate** combining high\-throughput screening with human\-relevant 2D/3D co\-culture capabilities * **Patent published** in 2024: **WO2024033549** * Technology designed for **scalable production** and ease of adoption * **Gravity\-driven microfluidics**, avoiding peripheral flow equipment * **Membrane\-free design**, reducing complexity and cost * Compatible with **standard plate readers** through a design\-for\-detection approach * Validated models already demonstrated in **intestine,** cartilage and tendon, with additional models under development including liver and kidney * Early industry validation and feedback through collaborations with **Leitat** and **ReadyCell** / MedTech Barcelona * The current microfluidic plate validation stage is **TRL 7** * Clear roadmap for spin\-off creation, beta testing and commercial operation **Current Founding Team** * **Pooya Azizian** – Future CTO * **Joan Marc Cabot** – Principal Investigator \& Advisor Head of Diagnostic Devices Group The project combines strong technical expertise in microfluidics and OoC systems with institutional backing and venture support from Leitat. **Your Role as CEO \& Co\-Founder (Next 6 Months)** You will lead OGYX through a critical transition phase focused on: * **Spin\-off creation** and shareholder structuring * Defining the **go\-to\-market strategy** for CROs, biotech, pharma and research groups * Validating the **business model** and pricing logic across standard plates, customized plates and modelling services * Structuring **early commercial traction** and beta\-testing strategy * Leading **private f**undraising efforts * Building partnerships with **CROs, biotech companies and pharmaceutical players** * Building engagement with regulatory agencies. * Supporting the strategic roadmap toward upscaling, product launch and new application development **The Offer** * **Relevant equity** as CEO \& Co\-Founder upon company incorporation * **€6,000 stipend** during the validation phase *(3 monthly instalments of €2,000\)* * Opportunity to access a **participative loan of up to €50,000** to finance the first phases of the project * Access to **The Collider venture\-building** programme, including: * Mentors and specialists in biotech, IP, go\-to\-market and fundraising * Support in spin\-off creation and shareholder structuring * Access to experts in life sciences and industrial strategy * **International exposure** through The Collider ecosystem *(4YFN, Mobile World Congress, corporate \& investor networks)* * **Coworking space in Barcelona** (Tech Barcelona – Pier 01\) * **Two years of post\-incorporation venture\-builder support**, including in\-kind services, community access and portfolio perks **This Opportunity Is for You If** * You are an entrepreneur with experience in biotech, life sciences, deep tech or scientific instrumentation * Previous experience as founder or co\-founder * Strong network in pharmaceutical sector * You understand the dynamics of drug discovery, CROs, pharma or advanced research tools * Experience in B2B sales, fundraising and strategic partnerships * Familiarity with platform business models and technology transfer is a strong plus * You are comfortable bridging science, product and business strategy * Eligible to work in Spain * Fluent in English and Spanish, Catalan is a plus.